Maternal alloimmunization occurs when a woman makes red blood cell antibodies as a result of foreign blood mixing. These antibodies can cross the placenta and attack the unborn child, a disease called hemolytic disease of the fetus and newborn (HDFN). HDFN can have devastating consequences including anemia, hyperbilirubinemia, and death. With close monitoring and timely treatment, babies with HDFN have a very high survival rate. Unfortunately, due to the rarity of alloimmunization and the variation in care practices around the world, well-managed pregnancies and ideal infant outcomes are not universal - but they can be!
The Allo Hope Foundation was founded to provide educational materials, family and provider support, and to promote research related to alloimmunization and HDFN.
Journey with our families as they go through pregnancy dealing with alloimmunization and HDFN.
Disclaimer: The purpose of this website is to provide general education, access to resources, and relevant literature. This website does not provide specific medical advice or recommendations for individual patients and is not a substitute for speaking with qualified healthcare professionals. The Allo Hope Foundation strongly recommends that care and treatment related to alloimmunization and HDFN be made in consultation with your physicians who are familiar with your individual health situation.
Our mission is to prevent any harm, stillbirth or infant death caused by alloimmunization and HDFN. We are dedicated to providing patient advocacy, support and education while promoting research and improving healthcare practices for the condition.